13. CLINICAL AND PARACLINICAL CHARACTERISTICS OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS TREATED AT THE NATIONAL DERMATOLOGY HOSPITAL FROM 01/2022 TO 8/2023
Main Article Content
Abstract
Objective: To describe the clinical and paraclinical characteristics of female systemic lupus erythematosus patients.
Subjects and methods: Study on a series of cases of 65 female systemic lupus erythematosus patients who came for examination and treatment at the National Dermatology Hospital from January 2022 to August 2023.
Results: The average age of disease was 30.72±15.1. The age group 10-19 accounts for the highest proportion (33.8%), and the age group 0-9 accounts for the lowest proportion (3.1%). The average duration of illness of the patients was 10.15±4.4 months. Skin lesions in SLE patients are diverse, including specific and nonspecific skin lesions. Acute skin lesions are the most common, accounting for 60%, followed by subacute 27.7% and chronic 12.3%. Butterfly rash lesions are most common in specific skin lesions (36.9%), and photosensitivity lesions are the most common in non-specific skin lesions (52.3%). The positive rate of Anti Smith autoantibodies is 23.1%; anti Ro/SSA was 46.2% and anti LA/SSB was 10.8%.
Conclusion: Skin lesions are very common and diverse in patients with systemic lupus erythematosus. Patients need to be examined carefully to detect early and fully all types of specific and non-specific lupus skin lesions, contributing to early diagnosis of SLE disease.
Article Details
Keywords
National hospital of dermatology & venereology, systemic lupus erythematosus, clinical, subclinical
References
Epidemiology of systemic lupus erythematosus:
a comparison of worldwide disease burden;
Lupus, 15(5), 2006, 308–318.101
[2] Chakravarty EF, Bush TM, Manzi S et
al., Prevalence of Adult Systemic Lupus
Erythematosus in California and Pennsylvania
in 2000: Estimates Using Hospitalization Data;
Arthritis Rheum, 56(6), 2007, 2092–2094.
[3] Olsen NJ, Kovacs WJ, Case report: testosterone
treatment of systemic lupus erythematosus in a
patient with Klinefelter’s syndrome; Am J Med
Sci, 310(4), 1995, 158–160.
[4] Shoenfeld Y, Cervera R, Gershwin ME et al.,
Diagnostic criteria in autoimmune diseases;
Humana Press, Totowa, NJ, 2008.
[5] Dubois’bLupus Erythematosus and Related
Syndromes-8th Edition.
related syndromes/9781437718935>, accessed:
24/06/2018.
[6] Gordon C, Long-term complications of systemic
lupus erythematosus; Rheumatology (Oxford),
41(10), 2002, 1095–1100.
[7] Sherer Y, Gorstein A, Fritzler MJ et al.,
Autoantibody explosion in systemic lupus
erythematosus: more than 100 different
antibodies found in SLE patients, Seminars in
Arthritis and Rheumatism, 2, 2004, 501–537.
[8] Cozzani E, Drosera M, Gasparini G et al.,
Serology of Lupus Erythematosus: Correlation
between Immunopathological Features and
Clinical Aspects. Autoimmune Dis. Epub 2014
Feb 6.
[9] Lê Huyền My, Nghiên cứu một số tự kháng thể
và mối tương quan với tổn thương da trên bệnh
nhân lupus ban đỏ hệ thống, Luận văn Tiến sĩ Y
học chuyên ngành Da Liễu, Trường Đại học Y
Hà Nội, 2018.
[10] Wang CL, Ooi L, Wang F, Prevalence and clinical
significance of antibodies to ribonucleoproteins
in systemic lupus erythematosus in Malaysia.
Rheumatology, 35(2), 1996, 129–132.
[11] Hussain N, Clinical and laboratory manifestations
of systemic lupus erythematosus in Pakistani
lupus patients; Pakistan Journal of Zoology,
45(3), 2013.
[12] Nguyễn Hữu Trường, Nghiên cứu mối tương
quan giữa mức độ hoạt động của bệnh với một số
tự kháng thể trong lupus ban đỏ hệ thống, Luận
án tiến sĩ, Đại học Y Hà Nội, 2017.
[13] Li J, Leng X, Li Z et al., Chinese SLE treatment
and research group registry: III. association
of autoantibodies with clinical manifestations
in Chinese patients with systemic lupus
erythematosus; Journal of immunology
research, 2014.
[14] Nguyễn Thị Hà Vinh, Mối liên quan giữa kháng
thể kháng Ro/SSA với biểu hiện lâm sàng, cận
lâm sàng của bệnh nhân lupus ban đỏ hệ thống,
Luận văn thạc sỹ y học, Đại học Y Hà Nội, 2014.
[15] Mowla MR, Alam M, Hoque MG et al., The
spectrum of cutaneous manifestations in lupus
erythematosus: the tertiary hospital experience;
Journal of Chittagong Medical College Teachers’
Association, 21(1), 2010, 34–39.
[16] Faria AC, Barcellos KSA, Andrade LEC,
Longitudinal fluctuation of antibodies to
extractable nuclear antigens in systemic lupus
erythematosus; The Journal of rheumatology,
32(7), 2005, 1267–1272.
[17] Sawalha AH, Harley JB, Antinuclear
autoantibodies in systemic lupus erythematosus.
Current opinion in rheumatology, 16(5), 2004,
534–540.
[18] Arroyo-Ávila M, Santiago-Casas Y, McGwin G et
al., Clinical associations of anti-Smith antibodies
in PROFILE: a multi-ethnic lupus cohort. Clin
Rheumatol, 34(7), 2015, 1217–1223.
[19] Patsinakidis N, Gambichler T, Lahner N et al.,
Cutaneous characteristics and association with
antinuclear antibodies in 402 patients with
different subtypes of lupus erythematosus. Acad
Dermatol Venereol, 30(12), 2016, 2097–2104.
[20] Cozzani E, Drosera M, Gasparini G et al.,
Serology of lupus erythematosus: correlation
between immunopathological features and
clinical aspects; Autoimmune diseases, 2014.
[21] Huỳnh Phan Phúc Linh, Nghiên cứu một số
kháng thể trên bệnh nhân lupus ban đỏ hệ thống
và một số yếu tố liên quan; Y học TP Hồ Chí
Minh, 2014, 148–154.
[22] Zaid FE, Abudsalam N, Cutaneous manifestation
of systemic lupus erythematosus [SLE],
correlation with specific organ involvement,
specific auto antibodies and disease activity and
outcome; Dermatol Case Rep, 1(108), 2, 2016.